TCF4 and plasma cell myeloma: Further studies have also demonstrated the ability of ECA treatment to lead to a reduction in LEF1 expression in myeloma MPC-11 cells, as well as a decrease in TCF-4 expression in myeloma OPM-2 cells, as reported by Schmeel et al. (2013) [43].